Clinical trials: Radiotherapy Side Effect
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Cancer, Radiotherapy Side Effect
Evaluation of Technological Innovation in Radiotherapy
Prospective cohort study of patients receiving standard-care radiotherapy is paramount to a better understanding of radiation effects and longterm outcomes.
- Trial name
- PERA (NCT03378856)
- Where
- 9 sites in Canada
- Volunteers
- 1,500 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral
Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
The purpose of this study is to assess the efficacity of N-acetylcystein against Cisplatin-induced ototoxicity.
- Conditions
- Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral, Ototoxicity, Tinnitus
- Trial name
- NCT04226456
- Testing
- N-acetyl cysteine
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Cardiotoxicity, DPP3
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year.
- Conditions
- Cardiotoxicity, DPP3, HSCT, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- ALLOCARDIOTOX (NCT07157670)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Pediatric ALL, Radiotherapy Side Effect
Design and Evaluation of Care Environment and Technology at Pediatric Radiotherapy
The purpose of the study is to evaluate the effect of changes in the care environment in pediatric radiotherapy. The definitions of the changes is a part of the study, and is constructed in collaboration with the institute of…
- Trial name
- DUMBO (NCT02993978)
- Volunteers
- 57 people
- Sponsor
- Umeå University
Cervical Cancer, Proton Therapy
Proton Therapy for Locally Advanced Cervical Cancer
The purpose of this protocol is to determine toxicity and efficacy of proton therapy in combination with standard concomitant platinum-based chemotherapy and standard image-guided adaptive brachytherapy (IGABT) in patients with…
- Conditions
- Cervical Cancer, Proton Therapy, Radiotherapy Side Effect
- Trial name
- NCT06462378
- Testing
- Proton therapy
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- University of Aarhus
Cardiotoxicity, Systolic Dysfunction
Aerobic Exercise is Cardio-protective in Hemato-oncological Disease and New-onset Chemotherapy
Oncological diseases are the main cause of death in developed countries and also in Uruguay. Advances in therapeutics have made possible to aspire to cure and in other cases long-term remission with a significant increase in…
- Conditions
- Cardiotoxicity, Systolic Dysfunction, Exercise, Aerobic
- Trial name
- AEROHEMONCO (NCT04476576)
- Testing
- Aerobic exercise (experimental), Flexibility exercise (active comparator)
- Where
- Uruguay
- Volunteers
- 38 people
- Sponsor
- Lucía Florio
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00003583
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Nasopharyngeal Cancer, Neoplasm Metastasis
Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions
Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.
- Trial name
- NCT03129412
- Testing
- radical radiotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Zhejiang Cancer Hospital
Adverse Radiation Effects, Radiation Necrosis
Microbiome Determinants of Adverse Effects of Stereotactic Radiosurgery
This prospective observational study will investigate the relationship between the gut microbiome and adverse effects following stereotactic radiosurgery (SRS).
- Trial name
- MICRO-ARE-SRS (NCT07767981)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Chicago
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Chronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder
Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment
Gynecological cancers, including those affecting the ovaries, uterus, and cervix, represent a significant health burden for women.
- Conditions
- Chronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder, Radiotherapy Side Effects, Side Effect of Chemotherapy
- Trial name
- OzoGynEpigen (NCT06816095)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Bernardino Clavo, MD, PhD
Coronary Microvascular Dysfunction, Cardiotoxicity
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy.
- Conditions
- Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
- Trial name
- NCT06332131
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, HER2-positive Breast Cancer
Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy
The introduction of trastuzumab for the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer has had a major impact upon cancer outcomes.
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Cardiotoxicity
- Trial name
- NCT05019365
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Breast Cancer
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan vs placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab.
- Trial name
- NCT00459771
- Testing
- AT1 blocker candesartan
- Where
- 19 sites in Netherlands
- Volunteers
- 210 people
- Sponsor
- The Netherlands Cancer Institute
Coronary Artery Disease, Cardiac Disease
The CAROLE (CArdiac Related Oncologic Late Effects) Study
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them…
- Conditions
- Coronary Artery Disease, Cardiac Disease, Cardiac Toxicity, Radiation
- Trial name
- CAROLE (NCT03235427)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Northwell Health
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Toxicity Due to Radiotherapy
Supplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast Cancer
Attention has been focused recently on the development of modalities that can protect healthy organs from the harmful effects of radiation applied during different cancer treatment schedules.
- Trial name
- ATHENA (NCT02195960)
- Testing
- intake anthocyanin-rich corn extract
- Where
- Italy
- Volunteers
- 242 people
- Sponsor
- Neuromed IRCCS
Lung Cancer, Metastases to Lung
A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY).
An open-label phase II study, investigating toxicity, treatment efficacy and the local tumor control rate in 69 patients with centrally located tumors and in 69 patients with ultra-centrally located tumors in the lung.
- Conditions
- Lung Cancer, Metastases to Lung, Radiotherapy Side Effect
- Trial name
- STRICTSTARLUNG (NCT05354596)
- Testing
- STRICT LUNG, STAR LUNG
- Where
- 6 sites in Denmark
- Volunteers
- 138 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet